Ok, just joking, I said from the future because the source is going to be published in January 2025.
NP18 is a promising new PROTAC degrader that targets the N-terminal domain (NTD) of the androgen receptor (AR), offering a potential solution for treating prostate cancer, especially CRPC cases with AR splice variants like AR-V7.
Unlike existing PROTACs that focus on the ligand-binding domain (LBD), NP18 can effectively degrade both full-length AR (AR-FL) and AR-V7. This is particularly important because AR-V7 lacks the LBD and drives resistance to current therapies.
Preclinical studies, including patient-derived xenograft models, have shown that NP18 exhibits superior antitumor activity compared to the NTD antagonist EPI-002. These findings suggest that NP18 could be a breakthrough in prostate cancer treatment.
Fight on bros!!!
Androgen Receptor Activity (ARA) for BAT
ADT vacation versus Continuous
Prostate cancer patients are better off with radiotherapy then surgery - new research
